Catalent

Kurt Nielsen, Ph.D., has been appointed chief technology officer and senior vice president of innovation and growth at Catalent Pharma Solutions, Inc. Dr. Nielsen will be responsible for driving innovation activities and investments across the company’s range of advanced dose forms and packaging technologies. Dr. Nielsen will report to John Chiminski, president and chief executive officer of Catalent, and will be based at the company’s global headquarters in Somerset, NJ.

Dr. Nielsen most recently served as executive vice president of pharmaceuticals for URLMutual Pharmaceutical Co., where he lead new product development and licensing activities for both products and drug delivery technologies, as well as the division’s manufacturing and quality operations. He had previously served as vice president, R&D at URLMutual and held R&D leadership positions with Teva Pharmaceuticals USA and the McNeil Consumer Products division of Johnson & Johnson.

“We are excited to have Kurt join the Catalent executive team. Catalent’s foundation was built on proprietary technologies, and Kurt’s experience and leadership will accelerate and deepen our innovation activities for existing and new platforms. With his deep background in both pharmaceutical sciences and commercial activities, Kurt is uniquely suited to ensure we align our more than 1,000 scientists and engineers to produce the new innovations that both our customers and their patients need,” said Mr. Chiminski.

Click here to find out more about Catalent